Preclinical study identifies vulnerability in orphan cancers with SMARCB1 mutations, spurs launch of Phase II clinical trial HOUSTON ― Researchers at The University of Texas MD Anderson Cancer Center have discovered that malignant rhabdoid tumors (MRT), a rare pediatric cancer without effective treatments, may be sensitive to drugs that block the cancer cell’s ability to dispose of misfolded proteins. The findings provide a much-needed therapeutic target for these and other cancers caused by mutations in the SMARCB1 gene. Based […]
